| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
19,740,000 |
| Market
Cap: |
4.17(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,297,189 |
| 52
Week Range: |
$120.4 - $292.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 27 |
| Insider 3/6 Months : 27.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
424,685 |
424,685 |
424,685 |
| Total Buy Value |
$0 |
$77,751,391 |
$77,751,391 |
$77,751,391 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
10 |
10 |
10 |
| Total Shares Sold |
252,542 |
270,142 |
270,142 |
339,631 |
| Total Sell Value |
$62,399,106 |
$66,219,580 |
$66,219,580 |
$85,688,008 |
| Total People Sold |
5 |
7 |
7 |
8 |
| Total Sell Transactions |
13 |
21 |
21 |
26 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Daly James M |
Director |
– • – |
2024-04-01 |
4 |
OE |
$100.45 |
$2,174,711 |
D/D |
21,577 |
22,775 |
|
- |
|
| Dier Mardi |
SVP and CFO |
• – – |
2024-03-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,875 |
|
-21% |
|
| Howarth Alex G. |
Chief Financial Officer |
• – – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,803 |
18,737 |
|
- |
|
| Lynch Brian Joseph |
SVP and General Counsel |
• – – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,639 |
17,691 |
|
- |
|
| Sibold William John |
President and CEO |
• • – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
12,250 |
62,250 |
|
- |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
5,786 |
20,787 |
|
- |
|
| Huntsman Carole |
Chief Commercial Officer |
• – – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,639 |
11,473 |
|
- |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,419 |
6,536 |
|
- |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2024-01-16 |
4 |
D |
$243.92 |
$134,156 |
D/D |
(550) |
5,117 |
|
- |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-01-16 |
4 |
D |
$243.92 |
$377,100 |
D/D |
(1,546) |
15,001 |
|
- |
|
| Lynch Brian Joseph |
SVP and General Counsel |
• – – |
2024-01-16 |
4 |
D |
$243.92 |
$231,480 |
D/D |
(949) |
14,052 |
|
- |
|
| Howarth Alex G. |
Chief Financial Officer |
• – – |
2024-01-16 |
4 |
D |
$243.92 |
$260,263 |
D/D |
(1,067) |
13,934 |
|
- |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2023-12-15 |
4 |
S |
$236.00 |
$477,000 |
D/D |
(2,000) |
5,667 |
|
15% |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2023-12-15 |
4 |
OE |
$87.92 |
$175,840 |
D/D |
2,000 |
7,667 |
|
- |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2023-12-14 |
4 |
S |
$232.00 |
$465,000 |
D/D |
(2,000) |
5,667 |
|
17% |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2023-12-14 |
4 |
OE |
$87.92 |
$175,840 |
D/D |
2,000 |
7,667 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • – |
2023-12-14 |
4 |
B |
$226.97 |
$4,710,893 |
I/I |
20,633 |
1,793,403 |
2.1 |
-17% |
|
| Baker Brothers Life Sciences Lp |
Director |
– • – |
2023-12-13 |
4 |
B |
$216.70 |
$17,805,684 |
I/I |
81,159 |
1,774,294 |
2.1 |
-14% |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2023-12-13 |
4 |
S |
$225.00 |
$563,500 |
D/D |
(2,500) |
5,667 |
|
14% |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2023-12-13 |
4 |
OE |
$87.92 |
$219,800 |
D/D |
2,500 |
8,167 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • – |
2023-12-12 |
4 |
B |
$205.32 |
$7,548,616 |
I/I |
34,578 |
1,699,129 |
2.1 |
-8% |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2023-12-12 |
4 |
S |
$216.00 |
$283,200 |
D/D |
(1,300) |
5,667 |
|
8% |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2023-12-12 |
4 |
OE |
$87.92 |
$114,296 |
D/D |
1,300 |
6,967 |
|
- |
|
| Craves Fred B |
Director |
– • – |
2023-12-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,556,594) |
1,261 |
|
- |
|
| Lynch Brian Joseph |
SVP and General Counsel |
• – – |
2023-12-05 |
4 |
S |
$227.33 |
$227,330 |
D/D |
(1,000) |
15,001 |
|
1% |
|
413 Records found
|
|
Page 2 of 17 |
|
|
6.07 (2.96%) 
